Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: BMK120|DRUG: Capecitabine|DRUG: BYL719|DRUG: Trastuzumab|DRUG: Lapatinib
Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: Novartis Pharmaceuticals